Differences in gene expression and alterations in cell cycle of acute myeloid leukemia cell lines after treatment with JAK inhibitors-Reference-Cited by-同舟云学术

Differences in gene expression and alterations in cell cycle of acute myeloid leukemia cell lines after treatment with JAK inhibitors

Published:2015-10 Issue: Volume:765 Page:188-197
ISSN:0014-2999
Container-title:European Journal of Pharmacology
language:en
Short-container-title:European Journal of Pharmacology

Author:

Gunerka Pawel,Dymek Barbara,Stanczak Aleksandra,Bujak Anna,Grygielewicz Paulina,Turowski Pawel,Dzwonek Karolina,Lamparska-Przybysz Monika,Pietrucha Tadeusz,Wieczorek Maciej

Publisher

Elsevier BV

Subject

Pharmacology

Reference67 articles.

1. Endogenous gene and protein expression of drug-transporting proteins in cell lines routinely used in drug discovery programs;Ahlin;Drug Metab. Dispos.,2009

2. Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F;Bandaranayake;Nat. Struct. Mol. Biol.,2012

3. Characterization of a human myeloid leukemia cell line highly resistant to taxol;Bhalla;Leukemia,1994

4. mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms;Bogani;PLoS One,2013

5. The myeloproliferative disorders;Campbell;N. Engl. J. Med.,2006

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of Ruxolitinib on Myeloproliferative Neoplasms via the Negative Regulators;Clinical Laboratory;2023

2. Recent researches for dual Aurora target inhibitors in antitumor field;European Journal of Medicinal Chemistry;2020-10

3. Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases;Journal of Cellular Physiology;2020-02-18

4. Rationally Repurposing Ruxolitinib (Jakafi®) as a Solid Tumor Therapeutic;Frontiers in Oncology;2016-06-13

5. Ruxolitinib synergizes with DMF to kill via BIM+BAD-induced mitochondrial dysfunction and via reduced SOD2/TRX expression and ROS;Oncotarget;2016-03-15